10 Best Medical Imaging Diagnostics for January 2026
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
The healthcare and technology sectors continue to show resilience amid market volatility, driven by innovation in diagnostics, medical imaging, and EV advancements. ValueSense analysis highlights stocks with strong intrinsic value potential, focusing on companies where current market prices may undervalue fundamentals like high gross margins, revenue growth, and quality ratings above 5.0. Selection criteria from ValueSense data emphasize Quality rating, Intrinsic value upside, positive 1Y Return trends, robust Free Cash Flow, and manageable Total Debt to Equity. These picks were filtered for diversified exposure across diagnostics leaders and growth plays, prioritizing those with ROIC above industry norms where possible and high FCF margins indicating operational efficiency. This methodology uncovers best value stocks in healthcare diagnostics and select tech, ideal for a stock watchlist.
Featured Stock Analysis
Stock #1: Agilent Technologies, Inc. (A)
| Metric | Value |
|---|---|
| Market Cap | $38.8B |
| Quality Rating | 6.8 |
| Intrinsic Value | $102.9 |
| 1Y Return | 3.4% |
| Revenue | $1,861.0M |
| Free Cash Flow | $1,466.0M |
| Revenue Growth | (71.4%) |
| FCF margin | 78.8% |
| Gross margin | 53.2% |
| ROIC | 4.9% |
| Total Debt to Equity | 49.8% |
Investment Thesis
Agilent Technologies, Inc. (A) stands out in the healthcare diagnostics space with a Market Cap of $38.8B and a solid Quality rating of 6.8. The company's Intrinsic value of $102.9 suggests significant undervaluation potential for investors analyzing fundamental metrics. Despite a recent Revenue growth of 71.4%, which reflects quarterly fluctuations, Agilent demonstrates exceptional profitability with a FCF margin of 78.8% and Free Cash Flow at $1,466.0M on Revenue of $1,861.0M. Strong Gross margin of 53.2% and ROIC of 4.9% underscore efficient capital use, while Total Debt to Equity at 49.8% indicates balanced leverage. This positions A as a stable pick in the medical imaging diagnostics theme for long-term stock analysis.
Key Catalysts
- Exceptional 78.8% FCF margin supports reinvestment and shareholder returns
- High Quality rating of 6.8 signals strong operational fundamentals
- 53.2% Gross margin reflects pricing power in life sciences and diagnostics
Risk Factors
- Negative Revenue growth of 71.4% may indicate cyclical pressures
- Modest 1Y Return of 3.4% trails sector peers
- ROIC at 4.9% could improve for higher capital efficiency
Stock #2: GE HealthCare Technologies Inc. (GEHC)
| Metric | Value |
|---|---|
| Market Cap | $37.7B |
| Quality Rating | 5.3 |
| Intrinsic Value | $160.8 |
| 1Y Return | 5.7% |
| Revenue | $20.2B |
| Free Cash Flow | $463.0M |
| Revenue Growth | 3.5% |
| FCF margin | 2.3% |
| Gross margin | 40.8% |
| ROIC | 10.7% |
| Total Debt to Equity | 19.6% |
Investment Thesis
GE HealthCare Technologies Inc. (GEHC), with a Market Cap of $37.7B, offers a Quality rating of 5.3 and an attractive Intrinsic value of $160.8, highlighting undervaluation in medical imaging. Steady Revenue of $20.2B pairs with Revenue growth of 3.5% and Free Cash Flow of $463.0M, though FCF margin is lower at 2.3%. The Gross margin of 40.8% and robust ROIC of 10.7% demonstrate profitability strength, complemented by low Total Debt to Equity of 19.6%. A 1Y Return of 5.7% reflects consistent performance, making GEHC a core holding for healthcare stock picks focused on diagnostics stability.
Key Catalysts
- Strong ROIC of 10.7% indicates efficient capital deployment
- Low Total Debt to Equity of 19.6% enhances financial health
- Scale from $20.2B Revenue provides market leadership in imaging
Risk Factors
- Low FCF margin of 2.3% limits cash generation flexibility
- Quality rating of 5.3 is moderate among peers
- Modest 1Y Return of 5.7% may lag high-growth names
Stock #3: Natera, Inc. (NTRA)
| Metric | Value |
|---|---|
| Market Cap | $31.1B |
| Quality Rating | 6.1 |
| Intrinsic Value | $84.9 |
| 1Y Return | 42.5% |
| Revenue | $2,116.7M |
| Free Cash Flow | $106.1M |
| Revenue Growth | 38.2% |
| FCF margin | 5.0% |
| Gross margin | 63.7% |
| ROIC | (57.5%) |
| Total Debt to Equity | 14.8% |
Investment Thesis
Natera, Inc. (NTRA) boasts a Market Cap of $31.1B, Quality rating of 6.1, and Intrinsic value of $84.9, positioning it as an undervalued growth play in genetic testing. Impressive Revenue growth of 38.2% on Revenue of $2,116.7M, with Free Cash Flow at $106.1M and FCF margin of 5.0%, signals scaling momentum. High Gross margin of 63.7% offsets negative ROIC of 57.5%, while low Total Debt to Equity of 14.8% supports balance sheet strength. The standout 1Y Return of 42.5% underscores momentum for undervalued stocks to buy in biotech diagnostics.
Key Catalysts
- Robust 38.2% Revenue growth drives expansion in cell-free DNA testing
- 63.7% Gross margin highlights premium product pricing
- Strong 1Y Return of 42.5% reflects market recognition
Risk Factors
- Negative ROIC of 57.5% indicates capital inefficiency
- Early-stage FCF margin of 5.0% vulnerable to R&D spend
- High growth may pressure margins if competition intensifies
Stock #4: Quest Diagnostics Incorporated (DGX)
| Metric | Value |
|---|---|
| Market Cap | $19.4B |
| Quality Rating | 6.4 |
| Intrinsic Value | $357.1 |
| 1Y Return | 15.7% |
| Revenue | $10.9B |
| Free Cash Flow | $1,393.0M |
| Revenue Growth | 13.7% |
| FCF margin | 12.8% |
| Gross margin | 33.3% |
| ROIC | 9.0% |
| Total Debt to Equity | 86.5% |
Investment Thesis
Quest Diagnostics Incorporated (DGX) features a Market Cap of $19.4B, Quality rating of 6.4, and compelling Intrinsic value of $357.1, suggesting deep undervaluation in lab services. Solid Revenue of $10.9B with 13.7% Revenue growth and exceptional Free Cash Flow of $1,393.0M (FCF margin 12.8%) highlight cash generation prowess. Gross margin of 33.3%, ROIC of 9.0%, and 1Y Return of 15.7% provide stability, despite higher Total Debt to Equity of 86.5%. This makes DGX a defensive healthcare stock pick for diversified watchlists.
Key Catalysts
- High FCF of $1,393.0M enables dividends and buybacks
- 9.0% ROIC supports consistent returns
- 13.7% Revenue growth from lab network expansion
Risk Factors
- Elevated Total Debt to Equity of 86.5% increases leverage risk
- Lower Gross margin of 33.3% vs. peers
- Regulatory changes in diagnostics could impact volumes
Stock #5: Exact Sciences Corporation (EXAS)
| Metric | Value |
|---|---|
| Market Cap | $19.3B |
| Quality Rating | 6.6 |
| Intrinsic Value | $71.2 |
| 1Y Return | 78.7% |
| Revenue | $3,082.0M |
| Free Cash Flow | $247.1M |
| Revenue Growth | 14.5% |
| FCF margin | 8.0% |
| Gross margin | 67.4% |
| ROIC | (22.3%) |
| Total Debt to Equity | 101.3% |
Investment Thesis
Exact Sciences Corporation (EXAS), at Market Cap $19.3B, earns a Quality rating of 6.6 with Intrinsic value of $71.2, appealing for cancer screening growth. Revenue of $3,082.0M grew 14.5%, generating Free Cash Flow of $247.1M (FCF margin 8.0%). Stellar Gross margin of 67.4% contrasts negative ROIC of 22.3%, with Total Debt to Equity at 101.3% and explosive 1Y Return of 78.7%. EXAS fits best value stocks in precision diagnostics.
Key Catalysts
- 78.7% 1Y Return captures screening adoption
- 67.4% Gross margin from proprietary tests
- 14.5% Revenue growth in molecular diagnostics
Risk Factors
- Negative ROIC of 22.3% reflects investment phase
- High Total Debt to Equity of 101.3%
- Dependence on reimbursement policies
Most investors waste time on the wrong metrics. We've spent 10,000+ hours perfecting our value investing engine to find what actually matters.
Want to see what we'll uncover next - before everyone else does?
Find Hidden Gems First!
Stock #6: Guardant Health, Inc. (GH)
| Metric | Value |
|---|---|
| Market Cap | $12.7B |
| Quality Rating | 5.4 |
| Intrinsic Value | $50.8 |
| 1Y Return | 220.2% |
| Revenue | $902.6M |
| Free Cash Flow | ($262.2M) |
| Revenue Growth | 30.4% |
| FCF margin | (29.1%) |
| Gross margin | 63.8% |
| ROIC | (92.7%) |
| Total Debt to Equity | (366.7%) |
Investment Thesis
Guardant Health, Inc. (GH) has a Market Cap of $12.7B, Quality rating 5.4, and Intrinsic value $50.8 amid liquid biopsy innovation. Revenue growth of 30.4% on $902.6M revenue shows promise, but negative Free Cash Flow of $262.2M and FCF margin of 29.1% indicate burn. High Gross margin 63.8%, deeply negative ROIC -92.7%, extreme Total Debt to Equity -366.7%, and massive 1Y Return 220.2% mark GH as high-risk/high-reward for stock picks.
Key Catalysts
- Phenomenal 220.2% 1Y Return from clinical adoption
- 30.4% Revenue growth in oncology testing
- 63.8% Gross margin supports path to profitability
Risk Factors
- Negative FCF $262.2M signals cash burn
- Poor ROIC -92.7% and Total Debt to Equity -366.7%
- Execution risks in competitive biotech space
Stock #7: NIO Inc. (NIO)
| Metric | Value |
|---|---|
| Market Cap | $12.5B |
| Quality Rating | 5.2 |
| Intrinsic Value | $6.7 |
| 1Y Return | 13.0% |
| Revenue | CN¥72.5B |
| Free Cash Flow | CN¥0.0 |
| Revenue Growth | 14.9% |
| FCF margin | 0.0% |
| Gross margin | 11.2% |
| ROIC | (72.7%) |
| Total Debt to Equity | 228.7% |
Investment Thesis
NIO Inc. (NIO), Market Cap $12.5B, scores Quality rating 5.2 with Intrinsic value $6.7 in EV tech. Revenue CN¥72.5B grew 14.9%, but Free Cash Flow CN¥0.0 and FCF margin 0.0% highlight challenges. Low Gross margin 11.2%, negative ROIC -72.7%, high Total Debt to Equity 228.7%, and 1Y Return 13.0% position NIO as a speculative tech diversifier.
Key Catalysts
- 14.9% Revenue growth from China EV demand
- Expanding battery-swapping network
- 13.0% 1Y Return amid sector recovery
Risk Factors
- Zero FCF and 0.0% FCF margin
- High Total Debt to Equity 228.7%
- Negative ROIC -72.7% and geopolitical risks
Stock #8: Revvity, Inc. (RVTY)
| Metric | Value |
|---|---|
| Market Cap | $11.5B |
| Quality Rating | 5.8 |
| Intrinsic Value | $138.3 |
| 1Y Return | -12.3% |
| Revenue | $2,813.4M |
| Free Cash Flow | $497.5M |
| Revenue Growth | 3.4% |
| FCF margin | 17.7% |
| Gross margin | 50.5% |
| ROIC | 3.2% |
| Total Debt to Equity | 47.8% |
Investment Thesis
Revvity, Inc. (RVTY), Market Cap $11.5B, has Quality rating 5.8 and Intrinsic value $138.3 for life sciences tools. Revenue $2,813.4M with 3.4% growth, strong Free Cash Flow $497.5M (FCF margin 17.7%), Gross margin 50.5%, ROIC 3.2%, Total Debt to Equity 47.8%, but negative 1Y Return -12.3%. Offers steady stock analysis exposure.
Key Catalysts
- Solid 17.7% FCF margin for resilience
- 50.5% Gross margin in high-tech tools
- Balanced Total Debt to Equity 47.8%
Risk Factors
- Negative 1Y Return -12.3%
- Low ROIC 3.2%
- Slow 3.4% Revenue growth
Stock #9: Qiagen N.V. (QGEN)
| Metric | Value |
|---|---|
| Market Cap | $9,783.1M |
| Quality Rating | 6.7 |
| Intrinsic Value | $62.5 |
| 1Y Return | 1.6% |
| Revenue | $2,070.8M |
| Free Cash Flow | $359.3M |
| Revenue Growth | 5.3% |
| FCF margin | 17.3% |
| Gross margin | 63.9% |
| ROIC | 8.8% |
| Total Debt to Equity | 0.0% |
Investment Thesis
Qiagen N.V. (QGEN), Market Cap $9,783.1M, leads with top Quality rating 6.7 and Intrinsic value $62.5 in molecular diagnostics. Revenue $2,070.8M grew 5.3%, Free Cash Flow $359.3M (FCF margin 17.3%), excellent Gross margin 63.9%, ROIC 8.8%, zero Total Debt to Equity 0.0%, and 1Y Return 1.6%. Prime undervalued stock candidate.
Key Catalysts
- Debt-free Total Debt to Equity 0.0%
- High 17.3% FCF margin and 8.8% ROIC
- 63.9% Gross margin from consumables
Risk Factors
- Modest 1Y Return 1.6%
- 5.3% Revenue growth lags hyper-growth peers
- Acquisition integration risks
Stock #10: NOV Inc. (NOV)
| Metric | Value |
|---|---|
| Market Cap | $5,936.7M |
| Quality Rating | 5.8 |
| Intrinsic Value | $24.4 |
| 1Y Return | 11.6% |
| Revenue | $8,775.0M |
| Free Cash Flow | $877.0M |
| Revenue Growth | (1.4%) |
| FCF margin | 10.0% |
| Gross margin | 20.5% |
| ROIC | 7.4% |
| Total Debt to Equity | 36.2% |
Investment Thesis
NOV Inc. (NOV), Market Cap $5,936.7M, scores Quality rating 5.8 with Intrinsic value $24.4 in energy equipment, adding commodity diversification. Revenue $8,775.0M dipped 1.4%, but Free Cash Flow $877.0M (FCF margin 10.0%), Gross margin 20.5%, ROIC 7.4%, Total Debt to Equity 36.2%, 1Y Return 11.6% provide balance.
Key Catalysts
- Strong 10.0% FCF margin in cyclical sector
- 11.6% 1Y Return from oilfield recovery
- Healthy 7.4% ROIC
Risk Factors
- Negative Revenue growth 1.4%
- Commodity price volatility
- Lower Gross margin 20.5%
Portfolio Diversification Insights
These 10 stocks cluster heavily in healthcare diagnostics (A, GEHC, NTRA, DGX, EXAS, GH, RVTY, QGEN) for 80% allocation, providing synergy in medical imaging and testing innovation, with NIO adding EV tech exposure and NOV commodities balance. High Quality ratings (avg. ~6.0) and intrinsic value upside create complementary growth-stability profiles—e.g., QGEN's zero debt offsets GH's negatives. Gross margins average ~48% support resilience, while varying ROIC encourages pairing high-return plays like NTRA (42.5% 1Y) with cash cows like DGX. This mix targets sector stock picks for reduced volatility via diagnostics dominance.
Market Timing & Entry Strategies
Consider entry during healthcare sector dips, such as post-earnings volatility or when intrinsic value gaps widen >20%. For growth names like NTRA/EXAS/GH, monitor Revenue growth acceleration; stable picks (A, DGX, QGEN) suit dollar-cost averaging. Track FCF trends quarterly—positive inflection signals strength. Use ValueSense screeners for undervalued stocks alerts, entering on pullbacks to 1Y lows with stops below key support. Position sizing: 5-10% per stock, favoring high Quality ratings.
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- Nelson Peltz - Trian Fund Management Portfolio Q3'2025: Top Holdings & Recent Changes
- Principles for Dealing with the Changing World Order by Ray Dalio
- The Ascent of Money by Niall Ferguson
- Principles for Navigating Big Debt Crises by Ray Dalio
- Influence: The Psychology of Persuasion by Robert B. Cialdini Ph.D.
FAQ Section
How were these stocks selected?
These stocks were selected using ValueSense criteria focusing on Quality rating >5.0, Intrinsic value upside, strong Gross margins, and sector diversity in healthcare/tech, pulled from diagnostics-themed screeners for best value stocks.
What's the best stock from this list?
QGEN stands out with the highest Quality rating 6.7, zero debt, 17.3% FCF margin, and 8.8% ROIC, ideal for conservative stock analysis—though all offer unique angles based on risk tolerance.
Should I buy all these stocks or diversify?
Diversify across 4-6 picks, weighting toward stable diagnostics (e.g., DGX, A) and growth (NTRA, EXAS), to balance healthcare stock picks while managing risks like negative ROIC in hyper-growth names.
What are the biggest risks with these picks?
Key risks include negative ROIC/FCF in growth stocks (GH, NTRA), high debt (EXAS, NIO), and sector regulation/commodity cycles (NOV), offset by strong margins and cash flows elsewhere.
When is the best time to invest in these stocks?
Optimal timing aligns with intrinsic value discounts >15-20%, positive Revenue growth inflections, or market rotations into healthcare—use ValueSense charting for entry signals on pullbacks.